Drug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 15, 2027

Study Completion Date

May 15, 2027

Conditions
Symptomatic Intracranial Atherosclerotic Stenosis
Interventions
DEVICE

NxiDIME™ Intracranial Drug-Eluting Stent System

The experimental group will receive the NxiDIME™ Intracranial Drug-Eluting self-expanding Stent System (RICOTON Technology Co., Ltd.)

DEVICE

NOVA DES Intracranial Drug-Eluting Stent

The experimental group will receive the NOVA DES Intracranial Drug-Eluting balloon-expandable stent System

Trial Locations (1)

100000

RECRUITING

A prospective, multi-center, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of the NxiDIME™ Intracranial Drug-Eluting Stent System in the treatment of symptomatic intracranial atherosclerotic stenosis lesions, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER